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Abstract
Malaria is a serious parasitic disease in the developing world, causing high morbidity and mortality. The
pathogenesis of malaria is complex, and the clinical presentation of disease ranges from severe and complicated,
to mild and uncomplicated, to asymptomatic malaria. Despite a wealth of studies on the clinical severity of disease,
asymptomatic malaria infections are still poorly understood. Asymptomatic malaria remains a challenge for malaria
control programs as it significantly influences transmission dynamics. A thorough understanding of the interaction
between hosts and parasites in the development of different clinical outcomes is required. In this review, the
problems and obstacles to the study and control of asymptomatic malaria are discussed. The human and parasite
factors associated with differential clinical outcomes are described and the management and treatment strategies
for the control of the disease are outlined. Further, the crucial gaps in the knowledge of asymptomatic malaria that
should be the focus of future research towards development of more effective malaria control strategies are
highlighted.
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Background
Malaria remains a serious global health burden, with an
annual incidence of 247 million cases and nearly one
million deaths, most of which afflict children living in
Africa [1]. Of the four human malaria parasite species,
Plasmodium falciparum is reported to cause the highest
morbidity and mortality. Young children with naïve
immune systems [2] and pregnant women with poten-
tially compromised immune systems are particularly vul-
n e r a b l et ot h i sd i s e a s ea n ds oa r ec o n s i d e r e dt ob et h e
highest risk populations for malaria-related deaths. P.
falciparum disease severity ranges from severe and com-
plicated, to mild and uncomplicated, to asymptomatic
[3,4]. Understanding the impact of P. falciparum on the
human host across this range is critical for learning how
to improve the management of the disease.
Generally, severe or complicated malaria has been at
the core of epidemiological studies because it is the
principal cause of malaria-related deaths. Researchers
and clinicians have established diagnostic criteria based
on the clinical manifestations upon disease onset, which
has aided in forming an integrated approach to improv-
ing the management and treatment of severe malaria.
Severe malaria is now defined by at least one of the fol-
lowing clinical manifestations: unrousable coma (caused
by cerebral malaria), convulsions, malarial anaemia, hae-
moglobinuria, hypoglycaemia, metabolic acidosis (asso-
ciated with respiratory distress), acute pulmonary
oedema, acute renal failure, jaundice, circulatory col-
lapse, hyperparasitaemia, high fever electrolyte distur-
bance, and/or spontaneous bleeding [4]. In areas of high
transmission, this full spectrum of clinical severity is pri-
marily observed in children; severe malaria is negatively
correlated with age due to the development of expo-
sure-related immunity in adults [5,6]. This is further
supported by finding that frequent exposure to P. falci-
parum malaria in high transmission regions typically
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lower transmission regions infrequent exposure extends
this period of risk [5].
In contrast, individuals with mild or uncomplicated
malaria typically present clinically with fever and per-
haps one or more of the following symptoms: chills and
sweats, headache, vomiting, watery diarrhea, anaemia,
jaundice, and swelling of the spleen (splenomegaly), but
do not generally have any of the features identified in
severe or complicated malaria [4]. If properly diagnosed
and treated, recovery success is high for patients with
uncomplicated malaria (reviewed in ref [6]). Uncompli-
cated malaria also occurs in endemic areas and is likely
associated with the development of some exposure-
related immunity. For example, Gupta et al. [7] reported
the development of clinical immunity to uncomplicated
malaria after only one or two infective bites, highlighting
the potential importance of strain-specific immunity.
Diagnosing asymptomatic malaria is not as straightfor-
ward due to the obvious lack of clinical manifestations
and often subpatent (undetectable by microscopy) level
of parasites [8]. Asymptomatic malaria is prevalent in
malaria endemic regions and has become a serious
cause for concern as efforts are increasing towards elim-
inating the parasite [9]. Particularly, subpatent malaria is
still transmissible and will complicate elimination of
malaria in high transmission regions. For example, a
study in Senegal suggested that more than 90% of
exposed individuals are likely infected with chronic
asymptomatic malaria [8], a situation in which the
majority of this population can then inadvertently act as
a reservoir for malaria transmission.
For more than two decades, researchers have investi-
gated the development of two types of immunity which
may result in asymptomatic malaria: 1) an anti-disease
immunity that allows one to carry parasite loads without
symptoms; and 2) an anti-parasite immunity that may
be responsible for the suppression of parasite loads after
a certain age, which is likely a factor of exposure-related
clinical immunity [10-12]. Interestingly, asymptomatic
malaria is not only limited to regions of high transmis-
sion where exposure-related immunity is expected to
develop; it has also been reported in the low transmis-
sion Amazonian regions of Peru, Brazil, and Columbia
and also the Solomon Islands [13-21]. Exposure-related
immunity may be achieved much earlier in life for indi-
viduals who live in low transmission regions due to pre-
dictably low parasite genetic diversity and few
overlapping infections.
F e wr e p o r t sa r ea v a i l a b l eo nt h es t u d yo fa s y m p t o -
matic malaria caused by species other than P. falci-
parum. However, like asymptomatic P. falciparum,
asymptomatic Plasmodium vivax malaria has been
reported in a range of endemic settings. For example,
the low transmission setting of Temotu Province, Solo-
mon Islands [20] and the highly endemic malaria area of
Rio Negro in the Amazon State, Brazil [22] both report
significant presence of asymptomatic P. vivax.A n o t h e r
Amazonia study reports that the prevalence of “symp-
tomless” falciparum and vivax malaria infections are 4-5
times higher than the symptomatic ones, with a signifi-
cant correlation of “symptomless” malaria with older age
groups [21]. Unfortunately, the reports above were lim-
ited to general prevalence surveys, without additional
molecular analyses.
Though rare, cases of Plasmodium malariae and Plas-
modium ovale asymptomatic infection have also
reported. A case report of transfusion-transmitted P.
malariae infection from an asymptomatic donor [23]
suggests that P. malariae can be harbored asymptomati-
cally. Supporting this, another study also reported a case
of malaria in a Grecian woman due to P. malariae
whose illness was reactivated after decades of latency
[24]. Infection with P. ovale can also be asymptomatic
[25]. However, these studies are mostly case reports and
extensive longitudinal studies are lacking. Therefore,
this review is focused on asymptomatic malaria due to
P. falciparum.
The purpose of this review is to: (1) critically examine
how asymptomatic falciparum malaria is defined; (2)
describe potential relationships to transmission
dynamics; (3) speculate on the potential roles of puta-
tively important parasite genes; (4) review human genes
that may contribute to susceptibility or resistance to
infection; (5) discuss the management and treatment of
asymptomatic malaria; and (6) discuss the gaps in
knowledge and highlight areas of future research.
The problem of defining asymptomatic malaria
A major obstacle in the study of asymptomatic malaria
is the lack of standard diagnostic criteria. For example,
infected individuals may be in a pre-symptomatic period
with parasitaemia, and present with clinical manifesta-
tions at a subsequent date [26]. Alternately, studies that
do not incorporate thorough clinical history surveys
may not capture individuals that may have experienced
symptoms for a brief period and then taken medication
that suppressed parasitaemia and symptoms. The most
widely-used criteria for diagnosis of asymptomatic
malaria are presence of parasites in peripheral thick
blood smears, an axillary temperature <37.5°C, and an
absence of malaria-related symptoms [27-30]. Some stu-
dies do include other criteria, such as longitudinal fol-
low-up and parasite quantification. Longitudinal follow-
up is particularly important for differentiating between
infections that appear asymptomatic at time of detec-
tion, but may become symptomatic after the initial
detection [19-33]. Quantifying parasitaemia, rather than
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important consideration when diagnosing asymptomatic
malaria. However, a universally standard parasite thresh-
old for classifying an infection as asymptomatic has yet
to be defined, as different studies use variable cut-off
levels for parasite density [31-33]. Though the use of
species-specific PCR possible is not always available in
the field, or even perhaps practical for testing infections
that are negative by microscopy, it is a powerful tool for
finding asymptomatic malaria within a population. For
example, Bottius et al. [8,34-36] found that as many as
two-thirds of the microscopy-negative patients had sub-
patent levels of parasites determined by diagnostic PCR,
indicating that almost the entire population was chroni-
cally infected with asymptomatic malaria. Examples of
the varied diagnostic criteria used to classify malaria as
asymptomatic by several different studies is presented in
Table 1. For a more comprehensive list, see Additional
file 1.
Transmission dynamics and asymptomatic malaria
Infection prevalence
The transmission dynamics of malaria are complex.
Even in endemic areas, transmission is not consistently
stable; rather, it can be patchy and dependent on factors
such as climate, the location of mosquito breeding sites,
and areas of clustered human habitations, which serve
as reservoirs of parasites for mosquito infection [39,40].
Asymptomatic infections often go undetected and
untreated, resulting in a major source of gametocytes
for local mosquito vectors [14]. Even in conditions
where the possibility of re-infection is excluded, P. falci-
parum infection has been shown to persist asymptoma-
tically in semi-immune individuals for more than 18
months [41]. Asymptomatic P. falciparum infections can
also persist inter-seasonally in regions with seasonal
transmission [42]. For example, even though the inci-
dence of clinical malaria in Senegal is significantly lower
during the dry season, a considerable proportion of the
population remain parasitaemic throughout the year
[29,43,44]. This reaffirms that malaria transmission can
persist in areas where symptomatic cases have been
monitored and treated. This model has driven presump-
tive intermittent anti-malarial treatment strategies for
the treatment of asymptomatic individuals, regardless of
their infection status, to reduce the disease burden.
In areas with annual malaria transmission, asympto-
matic P. falciparum parasitaemia is common among
immune inhabitants [45,46] and a large proportion of
individuals always harbor malaria parasites without any
associated clinical symptoms [47]. A positive correlation
between high transmission and high asymptomatic
Table 1 A wide range of diagnostic criteria is used for defining malaria patients as asymptomatic
Country
and Year
Criteria used for identifying asymptomatic malaria cases Study
subjects,
sample size
Follow-up protocol and duration Ref.
Africa
Gabon,
2003
No clinical symptoms of malaria with a P. falciparum positive
blood smear, asymptomatic for at least 5 days during follow-up.
Children
6 months to
10 years, N
=6 0
Examined once daily for 7 days thereafter, once
every 2 days
[37]
Tanzania,
2006
Presence of P. falciparum on blood smear, axillary temperature of
< 37.5°C, and no other symptoms or signs of malaria
Children
4-59 months,
N = 127
No follow-up. [33]
South America
Brazilian
Amazon,
2002
Individuals positive by microscopy, and/or positive by PCR; and
individuals negative by microscopy that subsequently became
positive by PCR.
All age
groups,
N = 172
Follow-up to day 10 and 60. [21]
Colombia,
2008
Presence of microscopic asexual parasite stages of P. falciparum,
P. vivax or P. malariae or of mixed infections in blood, which
persisted for at least two weeks without causing any symptoms,
or as the detection of parasite DNA by PCR on day 0 in people
who remained asymptomatic during the follow-up period.
Individuals
2-78 years,
N=2 1
Follow-up on days 14 and 28. [19]
Asia
Papua,
2003
No fever history or treatment for malaria within the past week, no
clinical evidence of malaria or other infection, no diarrhea, and no
current pregnancy but both P. falciparum and P. vivax positive
individuals
Adults
> 16 years,
N = 105
Supervised overnight at local health center. A
third axillary temperature was recorded the
following morning.
[38]
Indonesia,
2010
Presence of asexual P. falciparum or P. vivax parasitemia in the
absence of fever (temperature ≤ 37.9°C) and of clinical signs or
symptoms suggestive for malaria or another infectious disease.
Children
5-15 years,
N = 381
No follow-up. [27]
A more comprehensive list of studies is given in Additional file 1
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and Amazonian regions of Brazil [8,34-36]. Similarly, an
increase in the prevalence of asymptomatic vivax
malaria has been noted in high transmission regions,
including Thailand, Sri Lanka, and Brazil [48,49]. High
prevalence rates of asymptomatic malaria within areas
of high transmission might be due to exposure-related
immunity. Exposure-related immunity occurs when indi-
viduals who are frequently exposed to parasites for long
periods of time eventually develop immunological mem-
ory that suppresses infection. Paradoxically, asympto-
matic malaria has also been reported in low
transmission areas [15-21]. Two studies in the low
transmission Peruvian Amazon demonstrated that high
parasite exposure is not necessary for the development
of B-cell memory or long-lasting antibody titres [50,51].
Though exposure is thought to help maintain immuno-
logical memory, other factors besides the transmission
intensity may be associated with the prevalence of
asymptomatic malaria within different regions.
Mosquito infectivity
The production of gametocytes within an infected
human host is essential for transmitting the parasite to
the mosquito. Understanding the variables that are
involved in gametocyte production within the human
host, such as the host immune response to parasites,
anti-malarial drug treatment, and parasite genetic diver-
sity, and correlating these with the presence or absence
of symptoms, is layered with complexity. For example,
some studies have indicated that the quantity of gameto-
cytes may impact the level of mosquito infectivity [52];
however, asymptomatic carriers of sub-microscopic
gametocyte densities are also infectious to the mosquito
host, as found in some high transmission regions
[52,53]. It seems that the quality, not the quantity, of
gametocytes may be more important for infectivity
[53-59]. Anti-malarial drug treatment has been shown
to negatively impact gametocyte quality, by reducing
gametocyte infectivity upon a blood meal [60]. In turn,
this complicates controlled investigations of disease
severity and gametocyte infectivity of the mosquito host,
since more often than not, epidemiologists rely on asso-
ciation studies between gametocyte density or gameto-
cyte ratios and disease severity to extrapolate a possible
relationship.
There is evidence that patients with severe anaemia
have higher levels of gametocytes [61], which may be
the result of environmental cues released in the blood
upon parasite-induced haemolysis, or alternatively may
represent an artificial inflation due to the decreased
number of circulating red blood cells. An earlier study
also provided the evidence of this important relationship
between the development of patent P. falciparum
gametocytaemia and transmission potential [62]. The
study suggested that the sexual stages are not pyrogenic
and are commonly seen in subjects without fever, in
whom the asexual parasitaemia has fallen below the
pyrogenic threshold. This iss u p p o r t e db yf i n d i n gi n
their study that patients who were afebrile and pre-
sented with a low asexual parasitaemia were 2.7 times
more likely to present with a patent gametocytaemia
compared to those without both of these factors. Once
these sexual stages have been formed, they are harbored
and may persist for up to three weeks, imparting a per-
sistent ability to infect mosquitoes [63,64].
A study in Thailand investigating mosquito infectivity
differences between febrile and asymptomatic patients
reported that febrile patients were more infective than
asymptomatic individuals to mosquito hosts [65]. This
was recapitulated in a study in Amazonian natives,
which reported that highly parasitaemic, symptomatic
patients were more infective to mosquitoes than asymp-
tomatic patients with submicroscopic parasitaemia [14].
However, the authors reported that asymptomatic infec-
tions were 4-5 times more prevalent and infective for
longer periods of time post-treatment. In contrast,
Gouagna et al. reported that parasites from asympto-
matic individuals in an endemic region of western
Kenya were more infective to mosquitoes than parasites
from symptomatic individuals. The authors concluded
that this was a function of both the greater gametocyte
abundance in asymptomatic individuals and a higher
quality of infectious gametocytes [66,67].
These observations of asymptomatic malaria in low
and high endemic areas highlight the importance of car-
rying out active surveys for the identification of asymp-
tomatic carriers. The treatment of the infective parasite
reservoir of asymptomatic individuals may be an impor-
tant intervention strategy, and if this reservoir is greatly
reduced it will provide a positive impact on the inter-
vention of disease transmission.
Role of the malaria parasite in asymptomatic
malaria
It is not clear why some P. falciparum infections are
symptomatic while others are asymptomatic, but para-
s i t ef a c t o r sa r el i k e l yt ob ei n v o l v e d[ 6 8 ] .M a l a r i ap a r a -
sites influence disease outcome through factors that
include parasite density, rosetting and sequestration,
toxin production, and genetic diversity including expres-
sion of virulence and immune evasion genes such as the
var (variant antigen receptor) gene family.
Parasite density
The precise relationship between parasite density and
disease severity remains unclear, as the density of
sequestered parasites and circulating parasites varies
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the infection [69]. In general, high parasitaemia has
been associated with increased disease severity; however,
this is not always the case as peripheral parasitaemia
does not always accurately reflect the number of para-
sites due to sequestration. For example, Silamut et al.
reported cerebral malaria as the cause of death in apara-
sitaemic individuals in autopsies following effective anti-
malarial treatment [70]. A study in the Solomon Islands
showed that both P. vivax- and P. falciparum-infected
asymptomatic individuals tend to have low and submi-
croscopic parasite densities [20]. Another study sug-
gested the association of asymptomatic parasitaemia of
higher parasite density with a higher risk of sympto-
matic malaria [71].
A study investigating the relationship that parasite
density has on platelet count showed that malaria-
infected children with thrombocytopenia (decreased pla-
telet count) were younger, had higher parasitaemia,
lower hemoglobin levels, an increased mean platelet
volume, and exhibited platelet aggregation [72]. Simi-
larly, a cross-sectional study on Nigerian children with
asymptomatic malaria showed that malaria parasites
cause a significant reduction in platelet counts with
more pronounced reduction in children under 5 years
of age [73]. Therefore, thrombocytopenia is not only a
feature exhibited by acute malaria, but also a potentially
useful indicator for monitoring asymptomatic children
in high transmission areas.
Strain diversity
Various studies have investigated the genetic diversity of
P. falciparum and its association with the development
of clinical symptoms. There is strong evidence that
immunity to malaria is specific to the particular strain
eliciting the host response, enabling an individual to
resist infection by that particular strain, but not by het-
erologous ones; this has been termed ‘strain-specific
immunity’ [74-76]. The development of strain-specific
immunity might then be somewhat responsible for
decreased disease severity, including asymptomatic
malaria, in populations where exposure is moderate to
high.
Other studies have sparked an investigation of some
symptom-specific molecular characteristics based on
polymorphisms of surface antigens that have been iden-
tified in isolates collected from asymptomatic, uncompli-
cated, and severe malaria cases across various
geographic regions [77-79] (see Additional file 2). Such
polymorphic surface antigens include the merozoite sur-
face protein (MSP) family, apical membrane antigen 1
(AMA1), erythrocyte binding antigen-175 (EBA-175),
and knob-associated histidine rich protein (KAHRP).
Specific antigenic polymorphisms may allow the parasite
to evade the immune response in patients with chronic
infection and thus it may lead to their survival in the
human host until transmission becomes possible.
Merozoite surface proteins
Several studies have investigated the association of msp-
1 and msp-2 with clinical severity of disease. For exam-
ple, a study conducted to examine the relationship
between the genetic diversity of msp-1 block 2 of P. fal-
ciparum and clinical severity of malaria in Nigerian chil-
dren showed that the presence of K1 and MAD20
alleles were significantly associated with asymptomatic
malaria and consequently reduced the risk of developing
symptomatic disease [80]. Yet, it is possible that fre-
quency of exposure to these allelic families may also be
a factor. Ariey et al. [81] found that the association of a
specific msp-1 allele (K1) with a specific var gene (var-
D) was overrepresented among patients with severe
compared to mild disease, and this genotype combina-
tion was consistently observed in the most severe clini-
cal cases. However, investigations of genotype
associations with disease severity need to be expanded
to include all categories of disease, including asympto-
matic malaria. Further, genetic diversity should be longi-
tudinally monitored to ensure that such clinical
associations are maintained and not biased by cross-sec-
tional selection of isolates.
There are conflicting reports regarding the differential
distribution of alleles within particular genes (such as
msp-2) according to clinical status [82,83]. The FC27-
like genotype of msp-2 was shown to be twice as likely
to be found in symptomatic cases than in asymptomatic
cases [83], providing evidence that specific variants of
msp-2 may be associated with the morbidity of malaria.
A similar association was reported in Papua New Gui-
nea, where the FC27 allele was linked to increased dis-
ease severity, however, this study did not consider
asymptomatic cases [84]. Conversely, another study
reported that there was no association between FC27 or
3D7 alleles of msp-2 and malaria symptoms [85]. How-
ever, further longitudinal studies in different geographi-
cal settings with standardized collection and genotyping
methods will be required to clarify these findings.
Apical membrane antigen 1
Multiple lines of evidence indicate that polymorphisms
in the P. falciparum AMA1 domain I result from selec-
tive pressures exerted by protective host immune
responses [86]. In a study in Papua New Guinea, a pat-
tern of geographical diversity and the particular substi-
tutions found were suggestive of strong constraints
acting on the evolution of AMA1 at the population
level. In addition, differences between the sequences of
AMA1 domain I from symptomatic and asymptomatic
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the morbidity associated with a particular P. falciparum
strain [86].
Erythrocyte binding antigen 175
Studies on the distribution of EBA-175 genotypes sug-
gest that this gene plays a role in different clinical out-
comes. Genomic studies of two P. falciparum strains,
namely FCR-3 and CAMP, revealed two highly
dimorphic segments in region III, which is located in
the central part of the gene [87]. Dimorphism is referred
to as the F-fragment in the FCR-3 strain and the C-frag-
ment in the CAMP strain. In a study, the CAMP(C) and
FCR-3(F-) genotypes of the EBA-175 were encountered
in both symptomatic and asymptomatic patients, but the
FCR-3 genotype predominated regardless of clinical sta-
tus and the sampling period since the FCR-3(F-) geno-
t y p e sw e r es i m p l ym o r ep r e v a l e n ti nt h er e g i o n[ 2 2 ] .
However, the prevalence of mixed C-/F- infection was
far higher in symptomatic than in asymptomatic chil-
dren. This study showed that mixed C-/F- infection is
associated with clinical malaria and may have therapeu-
tic implications [32].
Virulence genes
An important aspect of P. falciparum virulence is the
ability of infected erythrocytes to sequester and obstruct
the microvasculature of different organs. Cytoadhesion
to endothelial cells is mediated by electron-dense eleva-
tions of the parasite membrane referred to as knobs.
Knobs consist predominantly of the knob-associated his-
tidine-rich protein (KAHRP), which cluster on the cyto-
plasmic face of the knob membrane [88]. KAHRP is
required for knob formation and has also been used as a
marker because of its role in pathology [89]. In one
study, three different alleles (340 bp, 370 bp and 400
bp) were found in mild cases, but only two forms (340
bp and 370 bp) were observed in severe cases [90]. Stu-
dies on the association of these KAHRP alleles with
severity need to be extended to asymptomatic malaria.
Many gene expression studies in P. falciparum have
focused on the diverse var gene family, encoding various
forms of erythrocyte membrane protein 1 (PfEMP1),
which is involved in cytoadherence of RBCs (red blood
cells) to endothelial cells [91]. Switching of PfEMP1 iso-
forms through differential expression of members of the
var multigene family is thought to facilitate evasion of
t h eh o s ti m m u n er e s p o n s e[ 9 1 , 9 2 ] .M o s tvar genes fall
into three major groups: var A, var B, and var C. Emer-
ging evidence suggests that specific expression of these
groups has clinical relevance and that major differences
in the transcription profile of var gene expression may
differentiate disease severity [33,93]. For example, var
group C transcript levels were increased in
asymptomatic cases, whereas transcripts of var group A
and B were abundant in patients with severe malaria
[33]. Another study reported that P. falciparum isolates
from cerebral malaria patients are significantly more
likely to transcribe var genes with DBLa1-like domains,
characteristic of Group A and Group B/A (an inter-
mediate group of var gene), than the isolates from
patients with non-severe hyperparasitaemia (i.e.,h i g h
parasitaemia with no symptoms or signs of severe dis-
ease) [94]. Recent studies on var gene expression and
malaria severity have yielded conflicting results
[33,93,95,96]. These studies are complicated by extensive
v a r i a t i o ni nt h evar gene transcription and the pheno-
types displayed by circulating parasites, which may be
different to those sequestered, as in severe malaria.
Therefore, comparing the repertoire of genomic and
expressed var genes with a particular malaria outcome
will be helpful to understand the role of this gene family
in asymptomatic malaria.
Other factors that influence malaria outcomes
The formation of rosettes may influence the severity of
malaria by causing distinct patterns of sequestration
with different pathogenic consequences [68]. Parasite
toxins such as glycosylphosphatidylinositol (GPI)
anchors and haemozoin have been proposed to drive
shock-like syndromes during infection [97,98]. However,
the roles of these factors have not been reported in
asymptomatic cases.
Intraleucocytic malaria pigment found in neutrophils
is suggested to be a better indicator of disease severity
than the peripheral parasite count [99,100]. Nguyen et
al. [100] first reported an increase in the proportion of
malaria-pigment containing neutrophils and monocytes
in severe malaria patients. Later, Amodu et al. [99] con-
firmed that there was an unambiguous rise in the pro-
portion of malaria pigment-containing neutrophils as
severity increases across a range of disease outcomes,
from uninfected to severe malaria cases. Amodu et al.
[99] also reported that the proportion of pigment-con-
taining monocytes did not differ significantly between
mild malaria, asymptomatic malaria, and no malaria
groups; however, the severe (cerebral) malaria group
had a higher median value than the other three groups.
Further, a case-control investigation [101] expanded and
validated the finding that monocytes and neutrophils are
markers of disease severity, but unfortunately asympto-
matic malaria cases were not assayed in this study.
Role of human host factors in clinical outcomes
Studies on the association of the roles of host factors
such as genes of the immune system, RBC polymorph-
isms or disorders, circulating levels of immunoglobulins
and cytokines, and pregnancy should not be limited
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matic malaria. To date this has usually not been the
case; the role of host factors in asymptomatic malaria
largely remains a field ripe for inquiry.
Polymorphisms of immunologically relevant genes
Significant correlations between SNPs (single nucleotide
polymorphisms) in regulatory or coding regions and
severe malaria have been reported for several immuno-
logically relevant genes, including cluster for differentia-
tion-40 ligand (CD40L), Fc gamma receptor II (FcgRII),
complement receptor 1 (CR1), tumor necrosis factor a
(TNF-a), interleukins -4, -12, and -13 (IL-4, IL-12, IL-
13), intracellular cell adhesion molecule-1 (ICAM-1),
CD-36, platelet endothelial cell adhesion molecule-1
(PECAM-1), toll-like receptor (TLR), and mannose
binding lectin 2 (MBL2)[102-115]. However, the associa-
tion between a particular SNP and response to infection
is highly dependent on ethnic background, i.e., an asso-
ciation demonstrated for one ethnic group may not be
t h es a m ef o rap o p u l a t i o nt h a td i f f e r sb o t hi ng e n e t i c
background as well as frequency of exposure to infec-
tion [116]. Thus, disease correlation with certain SNPs
inferred from studies of African or Caucasian popula-
tions may or may not yield the same results in ethnically
divergent or admixed populations. For example, allelic
and genotypic frequencies of interleukin-10 (IL-10-1087
A/G) and in IL-4-590 C/T polymorphisms have been
reported to vary based on inter-ethnic differences [117].
A study conducted in Gabon reported no statistically
significant association between MBL, TNFa-308, or
NOS2 polymorphisms and asymptomatic malaria [118].
However, this may not be true for other geographical
regions of the world. Studies on the genetic differences
between populations may provide a better understand-
ing of the role of these genes. A summary of the var-
iants and polymorphisms of the erythrocytic and
immunologically relevant genes of the human system
involved in malaria susceptibility and resistance is given
in Additional file 3.
RBC polymorphisms or disorders
Several RBC polymorphisms, like G6PD deficiency
[118,119], haemoglobin variants [120,121], ABO blood
group antigen [122], ovalocytosis [123], and polymorph-
isms in complement receptor 1 [124], have been shown
to provide at least some protection against severe
malaria, suggesting the possibility of coevolution
between parasite and host. Such protective roles are
much less clear for mild malaria and for asymptomatic
malaria [125].
However, research on G6PD polymorphisms has
expanded in the last decade to include a range of dis-
ease outcomes. For example, G6PD A
- heterozygosity in
females confers protection against all forms of malaria,
including the asymptomatic form [118]. The mechanism
of this protection may be because the parasite in G6PD
A
- heterozygous female host must cycle between G6PD
A
- and G6PD wild type erythrocytes and may fail to
adapt to the G6PD A
- environment [126].
The global distribution ofA B Ob l o o dg r o u pa n t i g e n s
reflects natural selection by various pathogens. There is
strong evidence that O blood group provides protection
against malaria by a mechanism of reduced rosetting
and sequestration [127], while other reports have found
an association between presence of blood group A with
higher incidence of severe malaria [128,129]. A study
that associated the blood groups of children with
malaria disease outcome, found a high prevalence of
asymptomatic malaria in children with the blood group
O antigen, when compared with those without this anti-
gen [121]. This study suggested that the blood group O
provides protection against clinical forms of malaria.
However, the association in this study was weak (p =
0.05). Further evidence for such protective effects must
not only consider the distribution of blood groups, but
also other explanations, such as the anti-rosette forma-
tion effect associated with blood group antigens [130].
Immunity due to circulating levels of immunoglobulins
and cytokines
Different clinical outcomes during malaria infection may
be due to differences in the host immunity level. Acqui-
sition of natural immunity to malaria has been observed
in high and stable (i.e., intense and constant over
months and years) malaria transmission areas. This
immunity acquired due to repeated exposure reduces
the risk of both severe and mild malaria. Therefore,
asymptomatic malaria could be a consequence of natural
immunity. However, in low transmission areas in South
America clinical immunity is found to develop in under-
exposed individuals, resulting in asymptomatic malaria
[50]. Hence, it could be possible that a person in a low
transmission area develops immunity faster because: (1)
there is less antigenic diversity circulating in the regions
and/or (2) there are less infections to overwhelm the
immune response [131,132].
Malaria infection induces polyclonal immunoglobulin
production the proportion of which determines protec-
tion against the blood stages of P. falciparum.E v i d e n c e
suggests that antibody-dependent mechanisms play an
important role in the reduction of parasitaemia and this
alleviates clinical symptoms, as demonstrated by the
passive transfer of hyper-immune immunoglobulin G
(IgG) [133,134]. Among the various IgG isotypes, cyto-
philic antibodies IgG1 and IgG3 have been consistently
correlated with uncomplicated malaria and even offer
protection, while IgG4 does not protect against malaria
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vations in total IgE, with higher levels detected in cere-
bral P. falciparum malaria than in uncomplicated mild
m a l a r i a[ 1 4 0 , 1 4 1 ] .T h er o l eo fa nti-parasite specific IgE
is, however, controversial. Some studies have observed
higher antimalarial IgE levels and functional activity in
asymptomatic and uncomplicated malaria groups than
in severe or cerebral malaria groups [30]. Additionally,
high anti-P. falciparum IgE levels have been associated
with a reduced risk of developing clinical malaria [142].
This supports a theory of IgE antibodies having a role in
protection against disease. Results from others studies
suggest that high levels of parasite-specific IgE are
observed in patients with severe malaria, which indicates
a putative role in pathogenesis [143-146].
One of the most challenging issues with studying
malaria immunology is that individuals at risk for
malaria infections are typically at risk for other parasitic
or non-parasitic diseases. Distilling the immunological
response induced by malaria apart from other infectious
diseases is not straightforward. For example, co-infection
of Plasmodium parasites with soil transmitted hel-
minthes or Hepatitis B Virus (HBV) has been reported
in several studies. Helminth infections may alter sus-
ceptibility to clinical malaria by changing the T-helper1/
T-helper2 (Th1/Th2) balance [147,148], thereby affect-
ing immunoglobulin levels. These findings are based on
the assumption that helminth infections induce a strong
and highly polarized immune response [149], which has
been suggested to help facilitate the acquisition of
immunity to malaria. In contrast, HBV when co-infected
with Plasmodium influences the malaria burden by sti-
mulating an increased inflammatory response. Plasmo-
dium-infected individuals with HBV infection were
more likely to be asymptomatic with lower levels of
parasitaemia and a decreased inflammatory cytokine
profile [150]. Thus, the host’s immune system is modi-
fied by other co-infecting organisms thereby complicat-
ing our understanding of malaria clinical outcome.
Age is considered one of the most important factors
that correlate with protective immunity in malaria ende-
mic areas. Infections among non-immune individuals
invariably result in clinical symptoms, and often lead to
death in young children if untreated [11]. Young chil-
dren are most susceptible to malaria infections and dis-
ease onset as they have not yet acquired clinical
immunity. In endemic areas, adults and older children
have a lower prevalence of malaria infection and lower
incidence of clinical malaria [151]. These individuals
acquire immunity from severe malaria episodes during
childhood [7] and therefore as an adolescent or adult
they are more likely to develop uncomplicated or
asymptomatic malaria than severe malaria [6]. Severe
cases are typically found in adults if they are non-
immune or have not encountered malaria before
[152,153].
In adult individuals, the acquired immunity or protec-
tion which is thought to keep their malaria asympto-
matic or uncomplicated could be due to increased
frequency of both type 1 and type 2 cytokine-producing
T cells [154]. Cytokines are involved in both protection
from, as well as the pathogenesis of, malaria infections.
Elevated levels of circulating cytokines such as interleu-
kin-6 (IL-6), IL-12, IL-1, and IL-10, as well as high cir-
culating levels of TNF-a, all appear to have some
correlation with the severity of the disease [111]. In fal-
ciparum malaria, cytokines may stimulate beneficial
immunological responses by inducing acute phase
responses, inhibiting parasite growth, and clearing vas-
cular parasites and debris. Inflammatory responses
mediated by interferon gamma (IFN-g) in the interleukin
12 (IL-12) and 18 (IL-18) dependent manner, seems to
be crucial for the control of parasitaemia through the
induction of tumor necrosis factor (TNF) and the
enhanced release of anti-parasitic reactive nitrogen and
oxygen radicals. TNF and INF-g stimulate neutrophils in
order to increase parasite destruction [155].
Pregnancy
Pregnant women are more susceptible to malaria infec-
tion, a phenomenon especially apparent during the first
pregnancy [156]. In successive pregnancies, a decrease
in intensity of infection has been observed and attribu-
ted to the acquisition of antibodies against variant sur-
face antigens (VSA) such as PfEMP-1 (P. falciparum
Erythrocyte Membrane Protein-1), rifins, and stevors.
These antigens are expressed on parasitized RBCs
infecting the placenta and are most commonly referred
to as Variant Surface Antigens of Pregnancy Associated
Malaria (VSA-PAM) [157,158]. The immunological rele-
vance of these biological factors associated with asymp-
tomatic malaria needs to be established. Studies on the
evaluation of cytokine and growth factor in asympto-
matic pregnant women showed an association between
increased plasma concentrations of IL-10 and G-CSF
[159].
Treatment and management of asymptomatic
malaria
Drug therapy has often been linked to the development
of gametocytaemia, as environmental pressure caused by
the targeted destruction of the asexual stage parasites
stimulates the production sexual stage parasites
(reviewed in [160]).Though this may be true, there is
also mounting evidence, found in studies like Bousema
et al. [161], which suggests that the production of game-
tocytes may be unrelated to drug therapy. In this study,
Bousema et al. [161] investigated gametocytaemia in a
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five years old). This study reported that despite a lack of
treatment, a significant proportion of these children had
quantifiable gametocytes. Therefore, asymptomatic indi-
viduals have the potential to develop gametocytes even
in the absence of drug therapy and this pool may serve
as reservoir of disease transmission.
Since the transmission of malaria parasites from
humans to mosquitoes requires the presence of gameto-
cytes, any strategy that interferes with the development
or persistence of gametocytes should help to interrupt
transmission. In most malaria endemic areas, the major-
ity of parasite carriers are asymptomatic [162] and these
carriers typically do not seek medical treatment. There-
fore, asymptomatic individuals carrying gametocytes
remain available as a reservoir for transmission by mos-
quitoes, contributing to the persistence of malaria trans-
mission within local populations [14,161].
The identification and management of asymptomatic
carriers has become a new and increasingly important
challenge for malaria control programs. One challenge,
in particular, is to reform the development of novel
anti-malarial drugs to include those that explicitly target
transmissible sexual stages. At the present, the majority
of anti-malarial drug treatments on the market target
the asexual blood stage of P. falciparum.T r e a t m e n t
regimens containing artemisinin and/or its derivatives
are reported to lower gametocyte carriage, and reduced
infectivity among treated individuals [163-165]. Artemi-
sinin combination therapy (ACT), which is advocated as
the first-line of anti-malarial treatment, and has been
reported to be efficient in reducing even submicroscopic
levels of gametocytes [55,164,166,167]. Intermittent pre-
ventive treatment (IPT), the administration of a full
course of an anti-malarial treatment to a population at
risk at specified time points regardless of the infection
status of individuals, has been proposed as a method of
treatment for asymptomatic individuals to reduce trans-
mission of disease. Artemether-lumefantrine, an ACT
drug currently available on the market, has been sug-
gested as a candidate for IPT treatment of asymptomatic
carriers [168]. The short half-life of lumefantrine makes
it an ideal treatment strategy because of concerns for
developing resistance to ACT. Pharmacokinetic determi-
nants of resistance selection indicate that this drug has
a considerably shorter “window of selection,” when com-
pared to other artemisinin companion drugs, such as
mefloquine [169].
Apart from selection for drug resistance, there is an
additional risk of the persistence of submicroscopic
gametocytes even after treatment, allowing for post-
treatment malaria transmission [166]. Primaquine, a
widely used drug for the treatment of P. vivax malaria,
actively clears submicroscopic P. falciparum
gametocytes [170-172], but the possible haemolytic
effects of primaquine in relation to G6PD deficiencies
must be considered before marketing this drug for the
treatment of gametocytes. Reports indicate that artesu-
nate (a derivative of artemisinin) may predominantly
inhibit gametocyte development, while primaquine may
accelerate its clearance [172]. However primaquine,
when given in combination with sulphadoxine-pyri-
methamine and artesunate, was found to be both safe
and highly efficient in clearing P. falciparum gameto-
cytes and asexual parasites detected by microscopy [173]
as well as submicroscopic gametocytes [174]. As part of
surveillance and control strategies for malaria, the sys-
tematic diagnosis or identification and treatment of
asymptomatic carriers could reduce the pool of parasites
available for the infection of mosquitoes.
The transmissibility of submicroscopic parasites within
asymptomatic malaria infections may help to drive the
persistence of malaria within endemic regions. The use
of antimalarial drug treatment (particularly ACTs), in
combination with insecticide treated nets (ITNs), long-
lasting insecticidal nets (LLINs), and indoor residual
spraying (IRS) is perhaps the most aggressive method
for reducing the malaria burden in endemic regions. A
recent study by Aregawi et al. [175] using ACT in com-
bination with ITNs/LLINs and IRS demonstrated a 76%
reduction in slide positivity for all age groups over a 4
year intensive intervention effort. Singling out the mos-
quito vector by undertaking comprehensive entomologi-
cal and ecological studies is necessary for fully
understanding malaria transmission dynamics, i.e.t h e
identification of vector breeding and resting sites, the
impact of climate change and temperature variation on
vector survival and capacity, and also insecticide
resistance.
Perspectives and future research
The history of research on asymptomatic malaria dates
back to 1900 when Robert Koch first identified such
cases in a study among patients in Papua New Guinea
[176]. Yet, asymptomatic malaria has rarely been a
major research focus. Since individuals with asympto-
matic malaria present with no symptoms, there are
inconsistencies in defining, difficulties in diagnosing,
and a general lack of urgency to investigate this parti-
cular disease outcome. In some sense, asymptomatic
malaria has become the “forgotten” malaria, although
recently asymptomatic malaria has become accepted as
a major hurdle for malaria elimination, as infected
hosts serve as silent reservoirs. The treatment of
asymptomatic carriers as part of routine surveillance
strategies has the potential to make a significant con-
tribution to the reduction of malaria in endemic
regions.
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asymptomatic malaria in endemic regions and establish-
ing a standard case definition for this malaria disease
outcome is a priority. To help facilitate this in field stu-
dies, longitudinal active case detection methods,
improved epidemiology questionnaires, and advanced
epidemiological modeling must become universal com-
ponents in all epidemiological studies. Concerted efforts
should also be directed towards the development of
highly sensitive, cheap and easily obtained rapid diag-
nostic detection kits, which can be used to detect parasi-
taemia at submicroscopic densities [177]. Identifying the
extent of the problem is a major challenge.
Secondarily, the underlying causes of asymptomatic
malaria must be fully investigated. It is important to
expand beyond the traditional association and correla-
tion analyses to include more comprehensive molecular
methods. If detection efforts are improved, then it will
be possible to discriminate between the host and para-
site roles in asymptomatic infection. Consequently, para-
site population diversity studies will become more
thorough, the association of parasite virulence genes will
become more relevant, and the malaria field will have a
better sense of how to interpret and manage different
disease outcomes. Importantly, information on host
genetics and immune responses in association with
asymptomatic malaria are severely lacking, but could
provide a wealth of knowledge on the management of
disease and the roles that they play in mounting differ-
ent responses to infection.
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Additional file 1: Diagnostic criteria for defining malaria patients as
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with different clinical outcomes of malaria. A. Human gene
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